SCORE2 versus SCORE in patients with systemic lupus erythematosus.

Juan Carlos Quevedo-AbeledoMiguel Angel González-Gay Iván Ferraz-Amaro

Published in: Therapeutic advances in musculoskeletal disease (2022)

In SLE patients, the ability of SCORE2 to predict the presence of subclinical atherosclerosis is higher than that of SCORE. According to our results, SCORE2, rather than SCORE, should be used in the CV risk stratification of patients with SLE. Prospective studies are needed to confirm these findings.

Keyphrases

systemic lupus erythematosus
ejection fraction
type diabetes
disease activity
case control